Literature DB >> 23446497

Feasibility of identifying a cohort of US women at high risk for HIV infection for HIV vaccine efficacy trials: longitudinal results of HVTN 906.

Beryl A Koblin1, Barbara Metch, Richard M Novak, Cecilia Morgan, Debbie Lucy, Debora Dunbar, Parrie Graham, Edith Swann, Tamra Madenwald, Gina Escamilia, Ian Frank.   

Abstract

BACKGROUND: Identifying cohorts of US women with HIV infection rates sufficient for inclusion in vaccine efficacy trials has been challenging. Using geography and sexual network characteristics to inform recruitment strategies, HVTN 906 determined the feasibility of recruiting a cohort of women at high risk for HIV acquisition.
METHODS: HIV uninfected women who reported unprotected sex in the prior 6 months, resided or engaged in risk behavior in local geographical high-risk pockets and/or had a male partner who had been incarcerated, injected drugs, or had concurrent partners were eligible. Behavioral risk assessment, HIV counseling and testing, and pregnancy testing were done at baseline, 6, 12, and 18 months.
RESULTS: Among 799 women, 71% were from local high-risk pockets and had high-risk male partners. Median age was 37 years; 79% were Black; and 15% Latina. Over half (55%) reported a new partner in the prior 6 months, 57% reported a male partner who had concurrent female sexual partners, and 37% reported a male partner who had been incarcerated. Retention at 18 months was 79.5%. Annual pregnancy incidence was 12%. Annual HIV incidence was 0.31% (95% confidence interval: 0.06% to 0.91%). Risk behaviors decreased between screening and 6 months with smaller changes thereafter. DISCUSSION: This cohort of women recruited using new strategies based on geography and sexual network characteristics did not have an HIV incidence high enough for HIV vaccine efficacy trials, despite high baseline levels of risk and a high pregnancy rate. New strategies to identify cohorts of US women for efficacy trials are needed.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23446497      PMCID: PMC3671573          DOI: 10.1097/QAI.0b013e31828ded1a

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  23 in total

1.  Characteristics associated with HIV infection among heterosexuals in urban areas with high AIDS prevalence --- 24 cities, United States, 2006-2007.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2011-08-12       Impact factor: 17.586

2.  Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.

Authors:  Robert M Grant; Javier R Lama; Peter L Anderson; Vanessa McMahan; Albert Y Liu; Lorena Vargas; Pedro Goicochea; Martín Casapía; Juan Vicente Guanira-Carranza; Maria E Ramirez-Cardich; Orlando Montoya-Herrera; Telmo Fernández; Valdilea G Veloso; Susan P Buchbinder; Suwat Chariyalertsak; Mauro Schechter; Linda-Gail Bekker; Kenneth H Mayer; Esper Georges Kallás; K Rivet Amico; Kathleen Mulligan; Lane R Bushman; Robert J Hance; Carmela Ganoza; Patricia Defechereux; Brian Postle; Furong Wang; J Jeff McConnell; Jia-Hua Zheng; Jeanny Lee; James F Rooney; Howard S Jaffe; Ana I Martinez; David N Burns; David V Glidden
Journal:  N Engl J Med       Date:  2010-11-23       Impact factor: 91.245

3.  Estimated HIV incidence among high-risk heterosexuals in New York City, 2007.

Authors:  Samuel M Jenness; Alan Neaigus; Christopher S Murrill; Travis Wendel; Lisa Forgione; Holly Hagan
Journal:  J Acquir Immune Defic Syndr       Date:  2011-02-01       Impact factor: 3.731

4.  Prevention of HIV-1 infection with early antiretroviral therapy.

Authors:  Myron S Cohen; Ying Q Chen; Marybeth McCauley; Theresa Gamble; Mina C Hosseinipour; Nagalingeswaran Kumarasamy; James G Hakim; Johnstone Kumwenda; Beatriz Grinsztejn; Jose H S Pilotto; Sheela V Godbole; Sanjay Mehendale; Suwat Chariyalertsak; Breno R Santos; Kenneth H Mayer; Irving F Hoffman; Susan H Eshleman; Estelle Piwowar-Manning; Lei Wang; Joseph Makhema; Lisa A Mills; Guy de Bruyn; Ian Sanne; Joseph Eron; Joel Gallant; Diane Havlir; Susan Swindells; Heather Ribaudo; Vanessa Elharrar; David Burns; Taha E Taha; Karin Nielsen-Saines; David Celentano; Max Essex; Thomas R Fleming
Journal:  N Engl J Med       Date:  2011-07-18       Impact factor: 91.245

5.  Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.

Authors:  Jared M Baeten; Deborah Donnell; Patrick Ndase; Nelly R Mugo; James D Campbell; Jonathan Wangisi; Jordan W Tappero; Elizabeth A Bukusi; Craig R Cohen; Elly Katabira; Allan Ronald; Elioda Tumwesigye; Edwin Were; Kenneth H Fife; James Kiarie; Carey Farquhar; Grace John-Stewart; Aloysious Kakia; Josephine Odoyo; Akasiima Mucunguzi; Edith Nakku-Joloba; Rogers Twesigye; Kenneth Ngure; Cosmas Apaka; Harrison Tamooh; Fridah Gabona; Andrew Mujugira; Dana Panteleeff; Katherine K Thomas; Lara Kidoguchi; Meighan Krows; Jennifer Revall; Susan Morrison; Harald Haugen; Mira Emmanuel-Ogier; Lisa Ondrejcek; Robert W Coombs; Lisa Frenkel; Craig Hendrix; Namandjé N Bumpus; David Bangsberg; Jessica E Haberer; Wendy S Stevens; Jairam R Lingappa; Connie Celum
Journal:  N Engl J Med       Date:  2012-07-11       Impact factor: 91.245

6.  Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial.

Authors:  Susan P Buchbinder; Devan V Mehrotra; Ann Duerr; Daniel W Fitzgerald; Robin Mogg; David Li; Peter B Gilbert; Javier R Lama; Michael Marmor; Carlos Del Rio; M Juliana McElrath; Danilo R Casimiro; Keith M Gottesdiener; Jeffrey A Chodakewitz; Lawrence Corey; Michael N Robertson
Journal:  Lancet       Date:  2008-11-13       Impact factor: 79.321

7.  The HVTN protocol 903 vaccine preparedness study: lessons learned in preparation for HIV vaccine efficacy trials.

Authors:  Gaston Djomand; Barbara Metch; Carmen D Zorrilla; Yeycy Donastorg; Martin Casapia; Tonya Villafana; Jean Pape; Peter Figueroa; Marianne Hansen; Susan Buchbinder; Chris Beyrer
Journal:  J Acquir Immune Defic Syndr       Date:  2008-05-01       Impact factor: 3.731

8.  Preexposure prophylaxis for HIV infection among African women.

Authors:  Lut Van Damme; Amy Corneli; Khatija Ahmed; Kawango Agot; Johan Lombaard; Saidi Kapiga; Mookho Malahleha; Fredrick Owino; Rachel Manongi; Jacob Onyango; Lucky Temu; Modie Constance Monedi; Paul Mak'Oketch; Mankalimeng Makanda; Ilse Reblin; Shumani Elsie Makatu; Lisa Saylor; Haddie Kiernan; Stella Kirkendale; Christina Wong; Robert Grant; Angela Kashuba; Kavita Nanda; Justin Mandala; Katrien Fransen; Jennifer Deese; Tania Crucitti; Timothy D Mastro; Douglas Taylor
Journal:  N Engl J Med       Date:  2012-07-11       Impact factor: 91.245

9.  Estimated HIV incidence in the United States, 2006-2009.

Authors:  Joseph Prejean; Ruiguang Song; Angela Hernandez; Rebecca Ziebell; Timothy Green; Frances Walker; Lillian S Lin; Qian An; Jonathan Mermin; Amy Lansky; H Irene Hall
Journal:  PLoS One       Date:  2011-08-03       Impact factor: 3.240

10.  Pregnancy incidence and correlates during the HVTN 503 Phambili HIV vaccine trial conducted among South African women.

Authors:  Mary H Latka; Katherine Fielding; Glenda E Gray; Linda-Gail Bekker; Maphoshane Nchabeleng; Koleka Mlisana; Tanya Nielson; Surita Roux; Baningi Mkhize; Matsontso Mathebula; Nivashnee Naicker; Guy de Bruyn; James Kublin; Gavin J Churchyard
Journal:  PLoS One       Date:  2012-04-19       Impact factor: 3.240

View more
  13 in total

1.  The HIV epidemic among women in the United States: a persistent puzzle.

Authors:  Danielle F Haley; Jessica E Justman
Journal:  J Womens Health (Larchmt)       Date:  2013-09       Impact factor: 2.681

2.  Rates of New Human Immunodeficiency Virus (HIV) Diagnoses After Reported Sexually Transmitted Infection in Women in Louisiana, 2000-2015: Implications for HIV Prevention.

Authors:  Daniel R Newman; Mohammad M Rahman; Antoine Brantley; Thomas A Peterman
Journal:  Clin Infect Dis       Date:  2020-03-03       Impact factor: 9.079

3.  HIV Sexual Risk and Syndemics among Women in Three Urban Areas in the United States: Analysis from HVTN 906.

Authors:  Beryl A Koblin; Shannon Grant; Victoria Frye; Hillary Superak; Brittany Sanchez; Debbie Lucy; Debora Dunbar; Parrie Graham; Tamra Madenwald; Gina Escamilia; Edith Swann; Cecilia Morgan; Richard M Novak; Ian Frank
Journal:  J Urban Health       Date:  2015-06       Impact factor: 3.671

Review 4.  Effect of race/ethnicity on participation in HIV vaccine trials and comparison to other trials of biomedical prevention.

Authors:  Shayesta Dhalla; Gary Poole
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

5.  Regression to the mean and changes in risk behavior following study enrollment in a cohort of U.S. women at risk for HIV.

Authors:  James P Hughes; Danielle F Haley; Paula M Frew; Carol E Golin; Adaora A Adimora; Irene Kuo; Jessica Justman; Lydia Soto-Torres; Jing Wang; Sally Hodder
Journal:  Ann Epidemiol       Date:  2015-03-21       Impact factor: 3.797

6.  Building Partnerships and Stakeholder Relationships for HIV Prevention: Longitudinal Cohort Study Focuses on Community Engagement.

Authors:  Rondalya D DeShields; Jonathan Paul Lucas; Melissa Turner; Kemi Amola; Valarie Hunter; Stephanie Lykes; Anne M Rompalo; Sten H Vermund; Suzanne Fischer; Danielle F Haley
Journal:  Prog Community Health Partnersh       Date:  2020

7.  Venue-based recruitment of women at elevated risk for HIV: an HIV Prevention Trials Network study.

Authors:  Danielle F Haley; Carol Golin; Wafaa El-Sadr; James P Hughes; Jing Wang; Malika Roman Isler; Sharon Mannheimer; Irene Kuo; Jonathan Lucas; Elizabeth DiNenno; Jessica Justman; Paula M Frew; Lynda Emel; Anne Rompalo; Sarah Polk; Adaora A Adimora; Lorenna Rodriquez; Lydia Soto-Torres; Sally Hodder
Journal:  J Womens Health (Larchmt)       Date:  2014-04-17       Impact factor: 2.681

8.  Feasibility of Identifying a Female Sex Worker Cohort at High Risk of HIV Infection in the Caribbean for HIV Vaccine Efficacy Trials: Longitudinal Results of HVTN 907.

Authors:  Marie M Deschamps; Barbara Metch; Cecilia A Morgan; Carmen D Zorilla; Yeycy Donastorg; Edith Swann; Dadaille Taina; Joseph Patrice; William J Pape
Journal:  J Acquir Immune Defic Syndr       Date:  2016-01-01       Impact factor: 3.731

9.  Retention strategies and factors associated with missed visits among low income women at increased risk of HIV acquisition in the US (HPTN 064).

Authors:  Danielle F Haley; Jonathan Lucas; Carol E Golin; Jing Wang; James P Hughes; Lynda Emel; Wafaa El-Sadr; Paula M Frew; Jessica Justman; Adaora A Adimora; Christopher Chauncey Watson; Sharon Mannheimer; Anne Rompalo; Lydia Soto-Torres; Zandraetta Tims-Cook; Yvonne Carter; Sally L Hodder
Journal:  AIDS Patient Care STDS       Date:  2014-04       Impact factor: 5.078

10.  T. vaginalis Infection Is Associated with Increased IL-8 and TNFr1 Levels but with the Absence of CD38 and HLADR Activation in the Cervix of ESN.

Authors:  Olamide D Jarrett; Kirsten E Brady; Sharada P Modur; Jill Plants; Alan L Landay; Mahmood Ghassemi; Elizabeth T Golub; Greg T Spear; Richard M Novak
Journal:  PLoS One       Date:  2015-06-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.